Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

Stephen E. Goldstone, Heiko Jessen, Joel M. Palefsky, Anna R. Giuliano, Edson D. Moreira, Eftyhia Vardas, Carlos Aranda, Richard J. Hillman, Daron G. Ferris, Francois Coutlee, J. Brooke Marshall, Scott Vuocolo, Richard M. Haupt, Dalya Guris, Elizabeth Garner

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.

Original languageEnglish
Pages (from-to)3849-3855
Number of pages7
Issue number37
StatePublished - 20 Aug 2013


  • HPV
  • Males
  • Men who have sex with men
  • Young


Dive into the research topics of 'Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males'. Together they form a unique fingerprint.

Cite this